// App-Quantinova.ai

5018 : Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

Researchers

Presenter

  • Daniel Peter Petrylak

Principal Investigators

  • Philip W. Kantoff

  • Anthony E. Mega

  • Nicholas J. Vogelzang

  • Joe Stephenson

  • Mark T. Fleming

  • Nancy Stambler

  • Michaela Petrini

  • Sara Blattman

  • Robert Joseph Israel

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Virginia Oncology Associates, Norfolk, VA

  • Cancer Centers of the Carolinas, Greenville, SC

  • Comprehensive Cancer Centers of Nevada, The US Oncology Network, Las Vegas, NV

  • Brown University Urology, Providence, RI

  • Yale University Medical School, New Haven, CT

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • Apparent diffusion coefficient

Drug/Treatment

  • PSMA ADC

  • taxane

  • monomethyl auristatin E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01414283

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved